The Canadian Cancer Trials Group (CCTG) is pleased to announce that our Director, Dr. Janet Dancey, has been elected to the Canadian Academy of Health Sciences (CAHS), which represents Canadian health sciences internationally and informs solutions that improve the health of all Canadians.
Dr. Dancey is an international leader in cancer clinical trials of experimental therapeutics and has special expertise in new anti-cancer drug development, linking drug and biomarker development, and associated clinical trials methodology, including development of novel trials for patients with rare tumours. As Director, she has advanced CCTG’s research strategy and expanded its portfolio dramatically. A prolific author with an excellent citation record, she is a sought-after speaker, both nationally and internationally.
In addition to being CCTG Director, Dr. Dancey is the Scientific Director of the Canadian Cancer Clinical Trials Network (3CTN) and was Director of the High Impact Clinical Trials Program at the Ontario Institute for Cancer Research. Prior to joining CCTG, she was Senior Clinical Investigator in the Cancer Therapy Evaluation Program at the US National Cancer Institute and then Associate Chief of the Investigational Drug Branch.
The CAHS elects individuals who have demonstrated leadership and creativity throughout their careers and have been recognized by their peers for their contributions to the promotion of health sciences. As a member of the CAHS, Dr. Dancey will spend the next three years providing analysis on, and solutions to, Canada’s most complex health concerns.
We would also like to congratulate all of the the 77 new 2020 CAHS Fellows with special mention to our CCTG colleagues:
Director, Charbonneau Cancer Institute and Professor, Clinical Neurosciences and
Oncology, University of Calgary
Professor, University of British Columbia
Wilson H. Miller Jr.
Medical Oncologist, Jewish General Hospital
Professor and Leslie Diamond Chair in Cancer Survivorship, Simon Fraser University
Professor Emeritus, Department of Internal Medicine, University of Manitoba
Professor, Senior Scientist, and Corinne Boyer Chair of Ovarian Cancer Research,
University of Ottawa and The Ottawa Hospital